We are live on ! Find out more
ACM

AIGH Capital Management Portfolio holdings

AUM $733M
1-Year Est. Return 327.32%
This Fund
S&P 500
This Quarter Est. Return
+5.95%
1 Year Est. Return
+327.32%
3 Year Est. Return
+1,033.66%
5 Year Est. Return
+1,660.59%
10 Year Est. Return
–
AUM
$333M
AUM Growth
+$80.2M
Cap. Flow
+$69.2M
Cap. Flow %
20.77%
Top 10 Hldgs %
65.42%
Holding
54
New
15
Increased
11
Reduced
11
Closed
11

Top Buys

Rank Stock Value
1
HUMA icon
Humacyte
HUMA
+$7.25M
2
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$6.51M
3
XAIR icon
Beyond Air
XAIR
+$6.38M
4
IPWR icon
Ideal Power
IPWR
+$6.06M
5
IMMX icon
Immix Biopharma
IMMX
+$6.02M

Top Sells

Rank Stock Value
1
ASPN icon
Aspen Aerogels
ASPN
+$28.5M
2
INDI icon
indie Semiconductor
INDI
+$18.3M
3
TGAN
Transphorm, Inc. Common Stock
TGAN
+$16.9M
4
SPRB
Spruce Biosciences
SPRB
+$6.22M
5
LPSN icon
LivePerson
LPSN
+$6.1M

Sector Composition

Rank Sector Weight
1 Healthcare 42.11%
2 Technology 14.5%
3 Industrials 5.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.97B
$94.9M 28.5%
+1,000,000
New +$92.8M
MU icon
2
CALL
Micron Technology
MU
$877B
$30.7M 9.2%
+260,000
New +$23.5M
SCPH
3
DELISTED
scPharmaceuticals
SCPH
$17M 5.11%
3,389,159
+282,364
+9% +$1.58M
OUST icon
4
Ouster
OUST
$2.15B
$14.7M 4.43%
1,857,114
– –
ELVA
5
Electrovaya
ELVA
$376M
$14.4M 4.32%
4,119,941
+766,633
+23% +$2.95M
CLRB icon
6
Cellectar Biosciences
CLRB
$20.2M
$11.2M 3.35%
93,497
+29,656
+46% +$3.21M
DCTH icon
7
Delcath Systems
DCTH
$400M
$11.1M 3.33%
2,359,728
+1,177,530
+100% +$5.08M
MYO icon
8
Myomo
MYO
$36.7M
$9.16M 2.75%
2,802,592
+134,302
+5% +$487K
TELA icon
9
TELA Bio
TELA
$30.9M
$8.02M 2.41%
1,415,255
+37,310
+3% +$246K
HUMA icon
10
Humacyte
HUMA
$166M
$6.71M 2.01%
+2,155,958
New +$7.25M
XAIR icon
11
Beyond Air
XAIR
$3.89M
$6.46M 1.94%
+9,286
New +$6.38M
COYA icon
12
Coya Therapeutics
COYA
$92.9M
$6.44M 1.93%
649,427
-382,550
-37% -$3M
FENC icon
13
Fennec Pharmaceuticals
FENC
$341M
$6.34M 1.9%
570,332
+240,962
+73% +$2.42M
IPWR icon
14
Ideal Power
IPWR
$56.3M
$6.23M 1.87%
700,000
+671,678
+2,372% +$6.06M
EGRX
15
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$6.22M 1.87%
+1,186,509
New +$6.51M
THTX
16
DELISTED
Theratechnologies
THTX
$6.16M 1.85%
3,725,204
+5,902
+0.2% +$9.47K
ALIM
17
DELISTED
Alimera Sciences
ALIM
$5.93M 1.78%
1,520,359
-705,709
-32% -$2.69M
OSPN icon
18
OneSpan
OSPN
$586M
$5.82M 1.75%
+500,000
New +$5.13M
PROF
19
Profound Medical
PROF
$264M
$5.52M 1.66%
646,733
– –
INFN
20
DELISTED
Infinera Corporation Common Stock
INFN
$5.36M 1.61%
+889,284
New +$4.46M
IDN icon
21
Intellicheck
IDN
$74.7M
$5.27M 1.58%
+1,514,026
New +$2.91M
LPTH icon
22
Lightpath Technologies
LPTH
$593M
$4.86M 1.46%
3,523,932
-200,000
-5% -$287K
BKTI icon
23
BK Technologies
BKTI
$293M
$4.83M 1.45%
330,896
– –
IMMX icon
24
Immix Biopharma
IMMX
$582M
$4.77M 1.43%
+1,555,000
New +$6.02M
BDSX icon
25
Biodesix
BDSX
$215M
$4.75M 1.43%
166,054
-66,893
-29% -$2.29M
1
2 3

Similar funds

GFI
Global Frontier Investments Charleston, South Carolina $732M AUM 8.6% 1-Year Est. Return
RP
Rice Partnership Honolulu, Hawaii $732M AUM 28.13% 1-Year Est. Return
IA
Intellus Advisors Naples, Florida $732M AUM 29.73% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
GIC
GFI Investment Counsel Toronto, Ontario, Canada $731M AUM 3.86% 1-Year Est. Return
CT
Colonial Trust Spartanburg, South Carolina $735M AUM 18% 1-Year Est. Return
TWP
TFO Wealth Partners Maumee, Ohio $735M AUM 21.07% 1-Year Est. Return
GWS
Glassman Wealth Services Vienna, Virginia $736M AUM 17.99% 1-Year Est. Return

AIGH Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, AIGH Capital Management held 54 positions worth $333M, up 32% from $253M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

AIGH Capital Management deployed $69.2M of net new capital in Q1 2024, opening 15 new positions and adding to 11 existing holdings. Its largest new stake was Humacyte: 2,155,958 shares worth $6.71M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, down from 56% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Brainsway, an estimated $4.96M trimmed.

  • AIGH Capital Management's largest Q1 2024 buy was Humacyte: 2,155,958 shares worth $6.71M.
  • AIGH Capital Management added most to Ideal Power in Q1 2024, an estimated $6.06M increase.
  • AIGH Capital Management's biggest Q1 2024 reduction was Brainsway, cutting an estimated $4.96M.
  • AIGH Capital Management fully exited Aspen Aerogels in Q1 2024, selling an estimated $28.5M.
  • AIGH Capital Management's ten largest holdings make up 65% of its $333M portfolio in Q1 2024.
  • AIGH Capital Management opened 15 new positions and closed 11 in Q1 2024.
  • AIGH Capital Management's portfolio value rose 32% quarter-over-quarter to $333M.

Based on AIGH Capital Management's 13F filing for Q1 2024, filed 14 May 2024.